Herma H Fidder
Overview
Explore the profile of Herma H Fidder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1420
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Te Groen M, Wijnands A, den Broeder N, de Jong D, van Dop W, Duijvestein M, et al.
Gut
. 2025 Jan;
74(4):547-556.
PMID: 39819862
Background: It remains unclear if the increased colorectal neoplasia detection rate in inflammatory bowel disease (IBD) by high-definition (HD) dye-based chromoendoscopy compared with HD white-light endoscopy is due to enhanced...
2.
Prins F, Hidding I, Klaassen M, Collij V, Schultheiss J, Uniken Venema W, et al.
Gut Microbes
. 2024 Aug;
16(1):2391505.
PMID: 39167702
Emerging evidence suggests the gut microbiome's potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response...
3.
van de Meeberg M, Sundaresan J, Lin M, Jansen G, Struys E, Fidder H, et al.
Basic Clin Pharmacol Toxicol
. 2024 Jul;
135(3):308-320.
PMID: 38973551
Background: Intracellular methotrexate polyglutamates (MTX-PGs) concentrations are measurable in red blood cells (RBCs) during MTX treatment. MTX-PG concentrations correlate with efficacy in patients with Crohn's disease (CD). Since RBCs are...
4.
van de Meeberg M, Fidder H, de Jonge R, Bouma G, Bulatovic Calasan M
Aliment Pharmacol Ther
. 2023 Dec;
59(1):120-121.
PMID: 38085943
No abstract available.
5.
van de Meeberg M, Fidder H, Oldenburg B, Sundaresan J, Struys E, Montazeri N, et al.
Aliment Pharmacol Ther
. 2023 Sep;
58(11-12):1151-1162.
PMID: 37767910
Background: Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease...
6.
Wijnands A, Elias S, Dekker E, Fidder H, Hoentjen F, Ten Hove J, et al.
United European Gastroenterol J
. 2023 Jul;
11(7):612-620.
PMID: 37505117
Background And Aims: Prior studies on the effect of smoking on the risk of colitis-associated colorectal neoplasia (CRN) have reported conflicting results. We aimed to further elucidate the association between...
7.
van de Meeberg M, Verheij E, Fidder H, Bouma G, Huitema A, Oldenburg B
Ther Drug Monit
. 2023 Feb;
45(5):668-675.
PMID: 36823707
Background: Therapeutic drug monitoring of mesalazine (5-ASA) in patients with ulcerative colitis is unavailable. Mucosal 5-ASA concentrations are assumed to be higher during remission, but biopsy is not practical. Therefore,...
8.
van de Meeberg M, Hebing R, Nurmohamed M, Fidder H, Heymans M, Bouma G, et al.
Br J Clin Pharmacol
. 2022 Nov;
89(1):61-79.
PMID: 36326810
Aims: In immune-mediated inflammatory diseases (IMIDs), early symptom control is a key therapeutic goal. Methotrexate (MTX) is the first-line treatment across IMIDs. However, MTX is underutilized and suboptimally dosed, partly...
9.
Mahmoud R, Savelkoul E, Mares W, Goetgebuer R, Witteman B, de Koning D, et al.
Clin Gastroenterol Hepatol
. 2022 Sep;
21(3):750-760.e4.
PMID: 36055567
Background & Aims: Discontinuation of anti-tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated with a high relapse risk that may be...
10.
Mahmoud R, Schultheiss J, Fidder H, Oldenburg B
Clin Gastroenterol Hepatol
. 2022 Apr;
21(2):558-559.
PMID: 35483605
No abstract available.